Post-Market Surveillance Is Getting Smarter: Real-World Data Trends in 2026
Regulators are increasingly expecting real-world evidence for device performance monitoring. We examine how FDA, EMA, and PMDA are leveraging registry data, and what this means for PMS system design.
The regulatory expectation for post-market surveillance has undergone a qualitative shift over the past several years, moving from a compliance documentation exercise toward a genuine evidence-generation discipline expected to produce real-world data capable of informing benefit-risk reassessment. FDA's National Evaluation System for health Technology — the NEST Coordinating Center — has published results from its first cohort of coordinated registry network studies, demonstrating that prospectively planned real-world evidence can meet evidentiary standards sufficient to support label expansions and post-approval study commitments. The 2025 NEST annual report documents eight completed studies across cardiovascular, orthopedic, and neuro-stimulation device categories, with four studies contributing data to active FDA regulatory decisions.
The European Medicines Agency's parallel push through the EU MDR Article 61 clinical follow-up framework and the EUDAMED database is creating a structured data infrastructure that regulators explicitly intend to use for population-level device performance monitoring. EUDAMED's clinical investigation and vigilance modules — now substantially populated following the MDR transition — allow the European Commission and national competent authorities to run cross-manufacturer analyses that were previously impossible. Our signal tracking shows a marked increase in EU competent authority requests for PMCF data initiated through EUDAMED queries rather than traditional surveillance correspondence, indicating that the database is moving from a passive repository toward an active analytical platform.
Japan's PMDA has taken a distinct but complementary approach, investing heavily in its Medical Device Registry System and creating formal pathways for registry operators to contribute data directly to the PMDA's benefit-risk monitoring functions. The agency's 2025 roadmap for real-world data explicitly references machine learning-assisted signal detection as a medium-term capability target, positioning PMDA to move from periodic scheduled reviews to continuous algorithmic surveillance of registry data streams. For manufacturers selling into Japan, this creates both an opportunity — proactively contributing high-quality registry data to PMDA is increasingly viewed favorably in approval reviews — and an obligation to ensure that PMS systems generate structured data compatible with registry ingestion requirements.
For PMS system designers and regulatory affairs professionals, these converging developments suggest several architectural principles. First, PMS systems must be designed to generate structured, queryable data from inception — unstructured complaint narratives and PDF-based periodic safety update reports will not meet the analytical expectations that NEST, EUDAMED, and PMDA's registry programs are establishing. Second, the unit of PMS analysis is shifting from the individual complaint record to the population-level performance trend, requiring statistical process control capabilities and pre-specified performance benchmarks against which field data can be evaluated. Third, the boundary between pre-market and post-market evidence generation is dissolving: the same registry infrastructure that satisfies post-market surveillance obligations is increasingly expected to contribute to label expansion evidence packages, making investment in high-quality real-world data collection a dual-use strategic asset.